EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy
(either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke
(composite of ischemic, hemorrhagic and unspecified stroke) in high-risk atrial fibrillation
(CHA2DS2-VASc ≥2) patients with previous intracranial hemorrhage.